Last year, CRO BioClinica saw its most rapid growth in Europe, the company said, and now, as it prepares to join forces with CCBR-Synarc in its second merger in as many years, the clinical trial outfit plans to deepen its investment in the continent.
Furiex Pharmaceuticals says it collected positive data from a pair of late-stage studies on its lead drug for irritable bowel syndrome. The developer expects the data to spur interest in a buyout based on what it sees as "blockbuster" potential for its therapy.
Canadian CRO Algorithme Pharma has expanded its Montreal clinic to include a dedicated unit for complex trials, adding 41 beds to its flagship facility.
A few days ago, as Pfizer executives reviewed the pharma giant's numbers for 2013 and plans for 2014, analysts detected a growing willingness to see if they could hunt up an accelerated approval for palbociclib if the Phase II study for breast cancer rang up promising results.
Aveo Oncology and Astellas Pharma are shutting down a Phase II study of tivozanib in breast cancer after failing to enroll enough patients, the partners announced.
Johnson & Johnson is the latest Big Pharma company that has vowed to open its clinical trial data vaults to the public, and to help it do that, it's enlisting the help of Yale University.
San Francisco's KaloBios is hitting the brakes on one of its lead programs after the asthma treatment missed its primary endpoint in a mid-stage trial, sending the company's shares into a 30% tailspin.
San Diego's Epic Sciences is working to expand access to its novel cancer diagnostic, joining forces with global giant LabCorp to make the test available to European drug developers.
DioGenix's MSPrecise test met its primary endpoint of identifying patients with multiple sclerosis, acing what the company said is the largest prospective diagnostic study of its kind for the disease.
Years of lax regulations helped India build a booming market for clinical trials, but a recent move to strengthen patient protections has deflated demand and last year saw just 19 studies get underway in the country, according to The Pharma Letter.